跳至主要内容
临床试验/NCT03037918
NCT03037918已完成不适用

Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans. A Large-cohort, Mechanistic Follow-up Study.

Loughborough University1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2017年2月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
56
试验地点
1
主要终点
Whole body insulin sensitivity index

研究概览

简要总结

Participants will be randomly allocated to either Yakult ingestion or a control group. For the first 20 days, subjects will consume their normal diet (keeping a detailed food diary throughout). On days 21-28 they will switch to a high-fat/high-calorie diet.

The investigators hypothesise that consuming a high-fat, high-energy diet for 7 days will alter the composition of the gut microbiota and induce metabolic endotoxaemia / systemic inflammation as well as decreasing whole body insulin sensitivity (as we have shown previously). In contrast, the investigators hypothesise that consuming Yakult for 21 days before and 7 days throughout the high-fat diet will maintain a favourable gut microbiota and prevent metabolic endotoxaemia / systemic inflammation and thus maintain insulin action / insulin sensitivity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

盲法说明

Participants will be given a unique identifier, which will not disclose the treatment group. All biological samples will be labelled with only the unique identifier.

入排标准

年龄范围
18 Years 至 30 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Males and females
  • •Aged 18-30
  • •Physically active (exercising at least 3 times per week for more than 30 min at a time)
  • •Non-smoker
  • •Free from cardiovascular or metabolic disease
  • •Weight stable for at least 6 months
  • •Normal body mass index (BMI: 18.5-24.9 kg/m2)*
  • •Compliant (i.e. understands and is willing, able and likely to comply with all study requirements)
  • •Note: If BMI is >24.9, but body fat % (as measured by bioelectrical impedance analysis) is below 21% in males and 31% in females, then the subject may still be recruited at the PI's discretion.

排除标准

  • •Using probiotic or prebiotic supplements within the previous 3 months
  • •Vegetarians and vegans
  • •Diagnosis of insulin resistance, pre-diabetes or full diabetes
  • •Underweight (determined as BMI less than 18.5 kg/m2)
  • •Overweight or obese (determined as BMI greater than 24.9 kg/m2)
  • •Those on a calorie controlled diet or other dietary restrictions that would prevent them from consuming the probiotic treatment and high fat/high calorie diet.
  • •Those who are unwilling to restrict their intake of fermented dairy products.
  • •Those with known or suspected food intolerances, allergies or hypersensitivity
  • •Women who are known to be pregnant or who are intending to become pregnant over the course of the study.
  • •Participation in another clinical trial
  • •Those who have donated blood within 3 months of the screening visit and participants for whom participation in this study would result in having donated more than 1500 ml of blood in the previous 12 months.
  • •Participants who take any form of regular medication that is known to affect either the gut microbiota and/or insulin sensitivity or who have taken any antibiotics in the previous 3 months.
  • •Participants who know they would not be available for all the lab visits during the 4-week study period.

研究组 & 干预措施

Treatment Group

Experimental

Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.

Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.

干预措施: Yakult light (Dietary Supplement)

Control Group

No Intervention

Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.

结局指标

主要结局

Whole body insulin sensitivity index

时间窗: The change between pre- and post-high fat diet (assessed on days 21 and 28)

Assessed by oral glucose tolerance test.

次要结局

  • Fasting serum insulin concentration(Day 0, Day 21 and Day 28)
  • Metabolic endotoxaemia(Day 0, Day 21 and Day 28)
  • Body Mass Index(Day 0, Day 21 and Day 28)
  • Fasting plasma glucose concentration(Day 0, Day 21 and Day 28)
  • Markers of systemic inflammation(Day 0, Day 21 and Day 28)
  • Fasting plasma triglyceride concentration(Day 0, Day 21 and Day 28)
  • Incretin response to glucose ingestion(Day 0, Day 21 and Day 28)
  • Microbiome analysis(Day 0, Day 21 and Day 28)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carl Hulston

Lecturer in Sports Nutrition

Loughborough University

研究点 (1)

Loading locations...

相似试验